Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13826222 | 0.87 | KMT2A (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL44677 | 0.86 | FABP5 (0.59) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL29381061 | 0.86 | FABP5 (0.59) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL29901230 | 0.86 | FABP5 (0.59) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL27503052 | 0.81 | HTR2A (0.42) | FABP5FABP7KMT2ACA1CA2 | |
| SCHEMBL30433255 | 0.80 | KMT2A (0.55) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL1250338 | 0.79 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| Isothiocyanate SCHEMBL30858893 | 0.78 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| Isothiocyanate SCHEMBL29261606 | 0.78 | FABP5 (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL1230997 | 0.77 | HTR2A (0.47) | FABP5FABP7KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190151-A1 | FLUORESCENTLY LABELED NUCLEOSIDE TRIPHOSPHATES AND ANALOGS THEREOF FOR SEQUENCING NUCLEIC ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2010-07-29 | — | — | US | disclosed |
| US-20100190151-A1 | FLUORESCENTLY LABELED NUCLEOSIDE TRIPHOSPHATES AND ANALOGS THEREOF FOR SEQUENCING NUCLEIC ACIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2010-07-29 | — | — | US | disclosed |
| US-20070117102-A1 | Nucleotide analogs | FLUIDIGM CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117102-A1 | Nucleotide analogs | FLUIDIGM CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117104-A1 | Nucleotide analogs | FLUIDIGM CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117104-A1 | Nucleotide analogs | FLUIDIGM CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117103-A1 | Nucleotide analogs | FLUIDIGM CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117103-A1 | Nucleotide analogs | FLUIDIGM CORPORATION | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117103-A1 | Nucleotide analogs | NT5C2, NT5C3B, NUDT1 | FABP5 2167/4885FABP7 4242/4885KMT2A 2259/4885 |
| US-20070117102-A1 | Nucleotide analogs | NT5C2, NT5C3B, NUDT1 | FABP5 2167/4885FABP7 4242/4885KMT2A 2259/4885 |
| US-20070117104-A1 | Nucleotide analogs | NT5C2, NT5C3B, NUDT1 | FABP5 2167/4885FABP7 4242/4885KMT2A 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.